乳癌组织端粒酶活性表达及其与p16基因的关系

目的：探讨乳房恶性肿瘤组织中端粒酶活性的表达情况及ｐ１６抑癌基因的影响。方法：应用端粒重复放大程序－酶标法（ＴＲＡＰ－ＥＬＩＳＡ）及ＴＲＡＰ－银染法检测３５例有乳癌组织及２４例良性肿瘤组织中的端粒酶活性，并采用多重ＰＣＲ技术对乳癌组织的ｐ１６基因的缺失空谈进行了分析，结果：３５例乳癌标本中有２８例端粒酶活性表达为阳性（８０％），而２４例乳房良性肿瘤标本中仅１例端粒酶活性表达阳性（４．１％）。此外３５例乳癌标本中的１５例存在有ｐ１６基因的外显子２及外显子１的缺失（４２．８％），而该１５例中有１４例被检测为端粒酶活性阳性（９３．３％），但２０例未缺失标本的端粒酶阳怀率仅为７０％（１４／２０）。结论：端粒酶活性与乳房肿瘤组织的恶性程度密切相关，提示端粒酶参与了肿瘤的形成过程，而端粒酶活性的增高与ｐ１６抑癌基因的缺失突

Telomerase aetivity and delation mutation of p16 gene in human breast cancer

Objectives:To study the expression of telomerase activity and effect of deletion mutation of p16 gene in human breast cancer.Methods:Telomerase activity was detected in 35 cases of breast cancer and 24 cases of benign breast tumor by TRAP-ELISA and TRAP-silver staining.Using multiplex PCR,deletion mutations of p16 gene in the breast cancer were analyzed too.Results:Telomerase activity was detected in 28 of 35(80%) cases of breast cancer,but only detected in 1 of 24(4.1%) cases of benign tumor.Deletion mutation of the exon 2 and exon 1 of p16 gene was discovered in 15 of 35 cancer specimens(43%).14 of the 15 deletion mutational cases (93%) were showed telomerase activity,while the positive rate of telomerase activity was found only 70%(14/20) in the unmutational cases. Conclusions:Telomerase activity may play an important role in the development of breast cancer,and there may be a link between telomerase activity and deletion mutation of p16 gene.